Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis

BAŞ O., Erul E., GÜVEN D. C. , AKSOY S.

SUPPORTIVE CARE IN CANCER, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Publication Date: 2022
  • Doi Number: 10.1007/s00520-022-07320-y
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Keywords: Cyclin-dependent kinase (CDK) 4/6 inhibitors, Abemaciclib, Palbociclib, Infection, Ribociclib, Neutropenia, FULVESTRANT, ABEMACICLIB, PALBOCICLIB, THERAPY, WOMEN
  • Hacettepe University Affiliated: Yes


Aim The combination of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors plus endocrine therapy (ET) improved the survival outcomes and became the standard of care in the treatment of metastatic hormone-positive breast cancer. However, these combinations increased the risk of neutropenia compared with ET alone. While the infection-related mortalities did not seem to be increased, the exact risk of infections with CDK 4/6 inhibitor and ET combinations is relatively understudied. Therefore, we performed a meta-analysis of CDK 4/6 inhibitor clinical trials to assess the infection risk of adding CDK4/6 inhibitors to ET.